1 day Ago By Defense World Staff
Bank of New York Mellon Corp grew its holdings in shares of AnaptysBio, Inc. ( NASDAQ:ANAB – Free Report ) by 16.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission.
The institutional investor owned 74,510 shares of the biotechnology company’s stock after buying an additional 10,423 shares during the quarter. Bank of New York Mellon Corp owned 0.27% of AnaptysBio worth $1,867,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the business. Trexquant Investment LP lifted its holdings in shares of AnaptysBio by 107.6% in the 4th quarter.
Trexquant Investment LP now owns 21,832 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 11,318 shares during the last quarter. Quest Partners LLC bought a new position in AnaptysBio in the 4th quarter worth about $119,000. Franklin Resources Inc.
increased its holdings in AnaptysBio by 22.7% during the 4th quarter. Franklin Resources Inc.
now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after purchasing an additional 75,025 shares during the period. First Light Asset Management LLC lifted its stake in AnaptysBio by 56.4% in the fourth quarter.
First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the period. Finally, Great Point Partners LLC grew its holdings in AnaptysBio by 9.2% during the 4th quarter.
Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after acquiring an additional 82,648 shares in the last quarter. Wall Street Analysts Forecast Growth Several research firms have issued reports on ANAB. Truist Financial lifted their price target on shares of AnaptysBio from $20.
00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. JPMorgan Chase & Co.
upped their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th.
Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of AnaptysBio in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company.
According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $50.30.
AnaptysBio Trading Down 3.2 % Shares of NASDAQ:ANAB opened at $37.50 on Wednesday.
AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $41.
31. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.
11 and a beta of -0.29. The business has a 50-day moving average price of $35.
23 and a 200 day moving average price of $27.63. AnaptysBio ( NASDAQ:ANAB – Get Free Report ) last released its quarterly earnings results on Monday, August 5th.
The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.
82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.
25%. The firm had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.
85 million. As a group, equities research analysts predict that AnaptysBio, Inc. will post -6.
84 earnings per share for the current fiscal year. Insider Transactions at AnaptysBio In other AnaptysBio news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average price of $36.
50 per share, for a total transaction of $9,999,978.00. Following the completion of the purchase, the insider now directly owns 7,794,996 shares in the company, valued at $284,517,354.
The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link . In other AnaptysBio news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of AnaptysBio stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average price of $36.
50 per share, for a total transaction of $9,999,978.00. Following the transaction, the insider now directly owns 7,794,996 shares in the company, valued at $284,517,354.
The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Also, Director Dennis M. Fenton sold 1,950 shares of the business’s stock in a transaction that occurred on Friday, June 21st.
The shares were sold at an average price of $23.17, for a total value of $45,181.50.
Following the completion of the transaction, the director now directly owns 1,950 shares in the company, valued at approximately $45,181.50. The disclosure for this sale can be found here .
In the last ninety days, insiders sold 34,390 shares of company stock valued at $1,239,012. 33.70% of the stock is currently owned by corporate insiders.
About AnaptysBio ( Free Report ) AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. See Also Five stocks we like better than AnaptysBio 3 Monster Growth Stocks to Buy Now Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Using the MarketBeat Dividend Tax Calculator Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge Where Do I Find 52-Week Highs and Lows? Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for AnaptysBio, Inc. ( NASDAQ:ANAB – Free Report ). Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.
com's FREE daily email newsletter ..
